Literature DB >> 1280990

Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells.

M B Parliament1, L I Wiebe, A J Franko.   

Abstract

Two aspects of the aerobic metabolism of nitroimidazole markers for hypoxia were investigated. Several normal murine tissues which are likely to be well oxygenated bind misonidazole at rates comparable to those of hypoxic regions in tumours. The possibility that this aerobic activation occurs via an oxygen independent process such as an initial two electron reduction was studied. Binding to the oesophageal mucosa of mice which occurred under hypoxia in vitro was inhibited by at least 95% in the presence of 10% oxygen. Dicoumarol, an inhibitor of DT-diaphorase, was shown to cause only small reductions in misonidazole binding to oesophageal epithelium and smooth muscle in vitro and to EMT6 tumours, liver, oesophageal and tracheal epithelium, parotid gland and smooth muscle in vivo. Thus an oxygen-insensitive process is not a major cause of the high binding rate in oesophageal mucosa, and may not contribute significantly to the observed binding in other normal tissues. It has been suggested that metabolism of nitroimidazoles by aerobic cells in tumours might be sufficient to minimise access of these compounds to hypoxic regions, particularly at the micromolar concentrations currently in use clinically. The uptake of 125I-iodoazomycin arabinoside by RIF-1 and EMT6 tumours was found to be directly proportional to injected dose over concentrations between 0.5 and 50 microM. Labelling of hypoxic regions in EMT6 tumours by high specific activity 3H-misonidazole at 1 microM was found to be similar to that obtained at 50 microM.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280990      PMCID: PMC1978026          DOI: 10.1038/bjc.1992.418

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: detection by F-19 nuclear magnetic resonance at 2.35 T.

Authors:  J A Raleigh; A J Franko; E O Treiber; J A Lunt; P S Allen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

2.  The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo.

Authors:  M R Horsman; P J Wood; D J Chaplin; J M Brown; J Overgaard
Journal:  Radiother Oncol       Date:  1990-05       Impact factor: 6.280

3.  Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro.

Authors:  A J Franko; C J Koch; B M Garrecht; J Sharplin; D Hughes
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

4.  Tissue distribution of 14C- and 3H-labelled misonidazole in the tumor-bearing mouse.

Authors:  L M Cobb; J Nolan; S Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-02       Impact factor: 7.038

5.  Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.

Authors:  G Akel; P Benard; P Canal; G Soula
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Misonidazole binding in murine liver tissue: a marker for cellular hypoxia in vivo.

Authors:  A P Maxwell; M P MacManus; T A Gardiner
Journal:  Gastroenterology       Date:  1989-11       Impact factor: 22.682

7.  DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs?

Authors:  P Workman; M I Walton; G Powis; J J Schlager
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

8.  Microscopic distribution of misonidazole in mouse tissues.

Authors:  L M Cobb; J Nolan; P O'Neill
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

9.  A novel technique for measuring human tissue pO2 at the cellular level.

Authors:  R C Urtasun; C J Koch; A J Franko; J A Raleigh; J D Chapman
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

10.  The effect of hypobaric hypoxia on misonidazole binding in normal and tumour-bearing mice.

Authors:  M P MacManus; A P Maxwell; W P Abram; J M Bridges
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

View more
  8 in total

1.  Electron paramagnetic resonance oximetry as a novel approach to monitor the effectiveness and quality of red blood cell transfusions.

Authors:  Huagang Hou; Jin H Baek; Hao Zhang; Francine Wood; Yamei Gao; Ann B Flood; Harold M Swartz; Paul W Buehler
Journal:  Blood Transfus       Date:  2019-05-16       Impact factor: 3.443

2.  Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.

Authors:  Quynh-Thu X Le; James Moon; Mary Redman; Stephen K Williamson; Primo N Lara; Zelanna Goldberg; Laurie E Gaspar; John J Crowley; Dennis F Moore; David R Gandara
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

3.  Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?

Authors:  Makiko Suehiro; Paul Burgman; Sean Carlin; Sean Burke; Guangbin Yang; Ouathek Ouerfelli; Christoph Oehler-Janne; Joseph O'Donoghue; Clifton Ling; John Humm
Journal:  Nucl Med Biol       Date:  2009-05-07       Impact factor: 2.408

4.  Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption.

Authors:  M B Parliament; A J Franko; M J Allalunis-Turner; B W Mielke; C L Santos; B G Wolokoff; J R Mercer
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 5.  Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.

Authors:  Annika Foehrenbacher; Timothy W Secomb; William R Wilson; Kevin O Hicks
Journal:  Front Oncol       Date:  2013-12-27       Impact factor: 6.244

6.  Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs.

Authors:  Dinghua Liang; Xing Wu; Brian B Hasinoff; David E Herbert; Geoffrey K Tranmer
Journal:  Molecules       Date:  2018-08-15       Impact factor: 4.411

7.  In vivo T cell activation in lymphoid tissues is inhibited in the oxygen-poor microenvironment.

Authors:  Akio Ohta; Rohan Diwanji; Radhika Kini; Meenakshi Subramanian; Akiko Ohta; Michail Sitkovsky
Journal:  Front Immunol       Date:  2011-07-05       Impact factor: 7.561

8.  Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver.

Authors:  G E Arteel; R G Thurman; J M Yates; J A Raleigh
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.